Vivek Ra­maswamy's 'van­t' brain­chil­dren keep bear­ing fruit with Urovan­t's FDA nod for in­con­ti­nence med vibegron

Christ­mas has come ear­ly for Urovant Sci­ences as the for­mer Vivek Ra­maswamy out­fit scored an FDA ap­proval for its lead pro­gram.

The biotech’s over­ac­tive blad­der can­di­date vibegron will be the newest drug to hit the mar­ket, the agency said Wednes­day, giv­ing Urovant its first ap­proved prod­uct. Vibegron, a be­ta-3 ag­o­nist that’s tak­en as a once-dai­ly pill, will be sold as Gemte­sa. The drug is like­ly to launch in ear­ly 2021, CEO James Robin­son has pre­vi­ous­ly said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER